zanosar
Pharmaranks rates Zanosar 2.7/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Zanosar (Streptozocin) is a medication used to treat Hodgkin Disease, Colorectal Neoplasms, Islet Cell Carcinoma.
Streptozocin · by Teva
⚠ FDA reports a current shortage of the powder, for solution form — availability differs between suppliers — see drug shortages →Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Streptozocin
- Form
- Powder
- Strength
- Streptozocin 1GM/VIAL
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- hodgkin disease, colorectal neoplasms, islet cell carcinoma
- Manufacturer
- Teva
- FDA application
- NDA050577
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
- hodgkin disease
- colorectal neoplasms
- islet cell carcinoma
Dosage forms
Powder
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Zanosar treat?
- Zanosar (Streptozocin) may be used to treat hodgkin disease, colorectal neoplasms, islet cell carcinoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Zanosar rated?
- pharmaranks gives Zanosar a composite score of 2.7 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Zanosar?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Zanosar. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Zanosar?
- Zanosar is marketed by Teva. You can see Teva's full profile, rating, and other products on pharmaranks.
- Is Zanosar a brand-name or generic drug?
- Zanosar is a brand-name product with the active ingredient Streptozocin.
- Is Zanosar available over the counter?
- No. Zanosar is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Zanosar come in?
- Zanosar is currently marketed as powder, per the FDA's National Drug Code Directory.
- Is Zanosar FDA-registered?
- Zanosar is on record with the U.S. FDA under application number NDA050577. You can verify this on its official FDA label.
- Has Zanosar been recalled by the FDA?
- Zanosar has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Zanosar safe?
- There's no single safe-or-not verdict. pharmaranks gives Zanosar a recall-safety score of 54/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about STREPTOZOCIN
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 197 reports naming STREPTOZOCIN — the active ingredient in Zanosar, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- malignant neoplasm progression62 reports
- pancreatic neuroendocrine tumour36 reports
- hypoglycaemia34 reports
- fatigue33 reports
- nausea27 reports
- decreased appetite24 reports
- weight decreased21 reports
- chronic kidney disease17 reports
Read these as a signal, not a rate. A report does not mean STREPTOZOCIN caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Zanosar head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
zanosar
54/100